People · Operator

Michael R. Campbell

Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals

1
Companies
1
Filings
$17.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$17.5M$31.4M2017
Operator network

Michael R. Campbell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Eldon R. Smith · 3 companies · 1 sharedEldon R. SmithEldon Smith · 2 companies · 1 sharedEldon SmithAmina Odidi · 1 companies · 1 sharedAmina OdidiAndrew Patient · 1 companies · 1 sharedAndrew PatientAndrew R. Patient · 1 companies · 1 sharedAndrew R. PatientBahadur Madhani · 1 companies · 1 sharedBahadur MadhaniBahadur R. Madhani · 1 companies · 1 sharedBahadur R. MadhaniIsa Odidi · 1 companies · 1 sharedIsa OdidiJohn N. Allport · 1 companies · 1 sharedJohn N. AllportKenneth Keirstead · 1 companies · 1 sharedKenneth KeirsteadKenneth R. Keirstead · 1 companies · 1 sharedKenneth R. Keirst…Patrick N. Yat · 1 companies · 1 sharedPatrick N. YatShameze N. Rampertab · 1 companies · 1 sharedShameze N. Ramper…Intellipharmaceutics International Inc. · $17.5M raisedIntellipharmaceutics …Michael R. CampbellMC
Michael R. Campbell Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Michael R. Campbell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Eldon R. Smith13
Eldon Smith12
Bahadur R. Madhani11
Shameze N. Rampertab11
Amina Odidi11
Isa Odidi11
Kenneth R. Keirstead11
Kenneth Keirstead11
Andrew Patient11
Bahadur Madhani11
John N. Allport11
Andrew R. Patient11
Patrick N. Yat11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.